Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC.
Brügmann A, Lelkaitis G, Nielsen S, Jensen KG, Jensen V
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to compare BRISH, FISH, and IHC analysis of tissue microarrays for the determination of HER2 status in breast carcinoma specimens. Tissue microarrays were prepared from formalin-fixed paraffin-embedded (FFPE) specimens that had been stored between 4 and 22 months. Liver tissue was included in tissue microarrays as a control.
Summary of Findings
HercepTest and PATHWAY showed 97% and 98% agreement with FISH results, respectively, both showed 99.4% specificity, but HercepTest had a lower sensitivity (78.3%) compared to PATHWAY (87%). If FISH results are taken as the reference standard, the same two cases which were misclassified by HercepTest were also misclassified by PATHWAY. In one case, polysomy of both HER2 and CEN17 explained the discrepancy between FISH and the IHC methods, while the other case was equivocal (2.01) by FISH and not amplified by both IHC methods. Almost perfect interobserver agreement was attained for the two BRISH methods. The overall agreement between the Dual ISH BRISH method and FISH was 98.5%, with a sensitivity of 96% and a specificity of 99%. For DuoCISH, the overall agreement with FISH was 93%, specificity was 93% and sensitivity was 96%.
Biospecimens
TissueBreastTissueLiverPreservation Types
FormalinDiagnoses
NeoplasticCarcinomaPlatforms
ProteinImmunohistochemistryProteinTissue microarrayDNAFISHDNATissue microarrayRNAIn situ hybridizationRNATissue microarrayMorphologyH-and-E microscopyPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Analyte Extraction and Purification Temperature of heat-induced retrieval 95 degrees C (PATHWAY)97 degrees C (HercepTest)In situ hybridization Specific Targeted nucleic acid CEN17HER2In situ hybridization Specific Technology platform Dual ISH (Ventana)DuoCISH (Dako)Immunohistochemistry Specific Technology platform HercepTest (Dako)PATHWAY (Ventana)FISH Specific Technology platform ImmunohistochemistryIn situ-hybridization